On Nov 18, 2021 BridgeBio Pharma closed a Post-IPO Debt round and raised $750,000,000 from investors, featuring lead investors .
About the company: BridgeBio Pharma is located at United States, North America.
“Targeting Genetic Diseases at Their Source”
Company website: http://www.bridgebio.com